Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)
- PMID: 29672914
- PMCID: PMC6171343
- DOI: 10.1002/JLB.5MR0118-028R
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)
Abstract
Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority.
Keywords: biomarkers; eosinophil-related disorders; eosinophilia; hypereosinophilic syndromes; murine models; translational research.
©2018 Society for Leukocyte Biology.
Conflict of interest statement
P.K., A.D.K., E.A.J., M.M., K.S., L.S., F.L.S., and R.G.S. have no conflicts of interest to disclose.
Figures
References
Publication types
MeSH terms
Grants and funding
- U19 AI136443/AI/NIAID NIH HHS/United States
- R21 AI122103/AI/NIAID NIH HHS/United States
- R01 AI105839/AI/NIAID NIH HHS/United States
- R56 AI121186/AI/NIAID NIH HHS/United States
- P01 HL107151/HL/NHLBI NIH HHS/United States
- U54 AI117804/AI/NIAID NIH HHS/United States
- R21 HL118588/HL/NHLBI NIH HHS/United States
- R21 AI132840/AI/NIAID NIH HHS/United States
- UG1 HL139117/HL/NHLBI NIH HHS/United States
- R37 AI020241/AI/NIAID NIH HHS/United States
- R01 HL124165/HL/NHLBI NIH HHS/United States
- R01 AI130033/AI/NIAID NIH HHS/United States
- R01 AI121186/AI/NIAID NIH HHS/United States
- K08 HL116429/HL/NHLBI NIH HHS/United States
- U01 AI097073/AI/NIAID NIH HHS/United States
- P01 HL088594/HL/NHLBI NIH HHS/United States
- U19 AI070235/AI/NIAID NIH HHS/United States
- R01 FD004086/FD/FDA HHS/United States
- R01 AI072265/AI/NIAID NIH HHS/United States
- K24 DK100303/DK/NIDDK NIH HHS/United States
- R01 AI124355/AI/NIAID NIH HHS/United States
- R01 HL065228/HL/NHLBI NIH HHS/United States
- R01 AR061567/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
